NYSE: AGL
agilon health, inc.CIK 0001831097 · SIC 8090 · Miscellaneous Health Services
Our business is transforming healthcare by empowering the primary care physicians (“PCP”) to be the agents for change in the communities they serve. We believe that PCPs, with their intimate patient-physician relationships, are best positioned to drive meaningful change in quality, cost and patient… About this business →
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (SPWH 10-Q) is open in full — no account needed.
Summary not yet generated.
agilon swings to $18.0M profit on 7.2% revenue growth, but litigation expands
5 material changes detected. Sign up free to read the summary.
Partner
Trade AGL commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
agilon health CTO Girish Venkatachaliah to depart Aug 1, receives $766k severance
2 material changes detected. Sign up free to read the summary.
agilon health holds routine annual meeting; directors elected, auditor and pay approved
3 material changes detected. Sign up free to read the summary.
agilon health reports Q1 2026 earnings results
2 material changes detected. Sign up free to read the summary.
revenue $1.42B, net income $48.9M. Agilon Health narrowly avoids NYSE delisting via 1-for-25 reverse split; interim CEOs in place
5 material changes detected. Sign up free to read the summary.
agilon health names Tim O'Rourke CEO with equity tied to $50-$150 stock price targets
5 material changes detected. Sign up free to read the summary.
agilon health executes 1-for-25 reverse stock split, shares begin trading March 31
4 material changes detected. Sign up free to read the summary.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 5, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Consolidated Statements of Operations (Unaudited)
(in thousands, except per share data)
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Revenues: | ||||
| Medical services revenue | 1,492,921 | 1,392,039 | 2,911,470 | 2,921,918 |
| Other operating revenue | 1,822 | 2,943 | 3,733 | 5,846 |
| Total revenues | 1,494,743 | 1,394,982 | 2,915,203 | 2,927,764 |
| Expenses: | ||||
| Medical services expense | 1,296,235 | 1,445,245 | 2,565,863 | 2,847,112 |
| Other medical expenses | 91,369 | 2,164 | 177,186 | 82,357 |
| General and administrative | 88,505 | 56,281 | 142,736 | 122,237 |
| Depreciation and amortization | 6,864 | 7,319 | 13,651 | 14,195 |
| Total expenses | 1,482,973 | 1,511,009 | 2,899,436 | 3,065,901 |
| Income (loss) from operations | 11,770 | (116,027) | 15,767 | (138,137) |
| Other income (expense): | ||||
| Income (loss) from equity method investments | (7,596) | 5,412 | 4,137 | 18,084 |
| Other income (expense), net | 15,015 | 7,879 | 31,040 | 17,140 |
| Interest expense | (1,608) | (1,572) | (3,419) | (3,087) |
| Income (loss) before income taxes | 17,581 | (104,308) | 47,525 | (106,000) |
| Income tax benefit (expense) | 375 | (62) | 347 | (258) |
| Income (loss) from continuing operations | 17,956 | (104,370) | 47,872 | (106,258) |
| Discontinued operations: | ||||
| Adjustments on sale of assets, net | — | — | 19,000 | 14,000 |
| Net income (loss) | 17,956 | (104,370) | 66,872 | (92,258) |
| Basic earnings per common share: | ||||
| Continuing operations | 1.07 | (6.31) | 2.88 | (6.43) |
| Discontinued operations | — | — | 1.14 | 0.85 |
| Net income (loss) | 1.07 | (6.31) | 4.02 | (5.58) |
| Diluted earnings per common share: | ||||
| Continuing operations | 1.04 | (6.31) | 2.84 | (6.43) |
| Discontinued operations | — | — | 1.12 | 0.85 |
| Net income (loss) | 1.04 | (6.31) | 3.96 | (5.58) |
| Weighted average shares outstanding | ||||
| Basic | 16,705 | 16,553 | 16,653 | 16,535 |
| Diluted | 17,213 | 16,553 | 16,884 | 16,535 |
Condensed Consolidated Balance Sheets
(in thousands, except per share data)
| Description | June 30, 2026 (unaudited) | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | 107,184 | 173,713 |
| Restricted cash and equivalents | 71,627 | — |
| Marketable securities | 78,443 | 111,429 |
| Receivables, net | 1,059,786 | 673,793 |
| Prepaid expenses and other current assets, net | 101,494 | 137,762 |
| Total current assets | 1,418,534 | 1,096,697 |
| Property, equipment, and capitalized software, net | 24,513 | 25,417 |
| Intangible assets, net | 60,132 | 65,725 |
| Other assets | 88,157 | 83,451 |
| Total assets | 1,591,336 | 1,271,290 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Current liabilities: | ||
| Medical claims and related payables | 1,022,506 | 929,770 |
| Accounts payable and accrued expenses | 274,928 | 127,477 |
| Current debt | 14,915 | 19,238 |
| Total current liabilities | 1,312,349 | 1,076,485 |
| Long-term debt | 15,377 | 15,750 |
| Other liabilities | 36,083 | 52,321 |
| Total liabilities | 1,363,809 | 1,144,556 |
| Commitments and contingencies | ||
| Stockholders' equity (deficit): | ||
| Common stock, $0.01 par value: 2,000,000 shares authorized; 16,785 and 16,589 shares issued and outstanding, respectively | 168 | 166 |
| Additional paid-in capital | 2,138,657 | 2,103,976 |
| Accumulated deficit | (1,911,452) | (1,978,324) |
| Accumulated other comprehensive income (loss) | 154 | 916 |
| Total stockholders’ equity (deficit) | 227,527 | 126,734 |
| Total liabilities and stockholders’ equity (deficit) | 1,591,336 | 1,271,290 |
Condensed Consolidated Statements of Cash Flows (Unaudited)
(in thousands)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net income (loss) | 66,872 | (92,258) |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||
| Depreciation and amortization | 13,651 | 14,195 |
| Stock-based compensation expense | 30,087 | 32,101 |
| Loss (income) from equity method investments | (4,137) | (18,084) |
| Adjustments on sale of assets, net | (19,000) | (14,000) |
| Other, net | 1,377 | (3,107) |
| Changes in operating assets and liabilities | (122,419) | 14,081 |
| Net cash provided by (used in) operating activities | (33,569) | (67,072) |
| Cash flows from investing activities: | ||
| Purchases of property, equipment, and capitalized software | (6,548) | (7,099) |
| Purchase of intangible assets | (885) | (9,717) |
| Investment in loans receivable and other | — | (1,000) |
| Investments in marketable securities | — | (60,154) |
| Proceeds from maturities of marketable securities and other | 46,616 | 125,339 |
| Net cash provided by (used in) investing activities | 39,183 | 47,369 |
| Cash flows from financing activities: | ||
| Proceeds from (payments for) equity issuances, net | 4,596 | (2,741) |
| Debt issuance costs | (1,612) | — |
| Repayments of long-term debt | (3,500) | — |
| Net cash provided by (used in) financing activities | (516) | (2,741) |
| Net increase (decrease) in cash, cash equivalents and restricted cash and equivalents | 5,098 | (22,444) |
| Cash, cash equivalents and restricted cash and equivalents, beginning of period | 173,713 | 193,860 |
| Cash, cash equivalents and restricted cash and equivalents, end of period | 178,811 | 171,416 |
Amounts as printed on the EDGAR/iXBRL face — (in thousands, except per share data); (in thousands). Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗
View AI report for this filing
About agilon health, inc.
Source: Item 1 (Business) from the 10-K filed February 25, 2026. Description as filed by the company with the SEC.
ITEM 1. Business
Overview
Our business is transforming healthcare by empowering the primary care physicians (“PCP”) to be the agents for change in the communities they serve. We believe that PCPs, with their intimate patient-physician relationships, are best positioned to drive meaningful change in quality, cost and patient experience when provided with the right infrastructure and payment model. Through our combination of the agilon platform, a long-term partnership model with existing physician groups and a growing network of like-minded physicians, we believe we are poised to revolutionize healthcare for seniors across communities throughout the United States (“U.S.”). We believe our purpose-built model provides the necessary capabilities, capital and business model for existing physician groups to create a Medicare-centric, globally capitated line of business. Our model operates by primarily forming risk-bearing entities (“RBEs”) within local geographies, that enter into arrangements with payors providing for monthly payments to manage the total healthcare needs of our physician partners’ attributed patients (or global capitation arrangements). The RBEs also contract with agilon to perform certain functions and enter into long-term professional service agreements with one or more anchor physician groups pursuant to which the anchor physician groups receive a base compensation rate and share in the savings from successfully improving quality of care and reducing costs.
Our company was formed in 2016, and we established our inaugural partnership with an anchor physician group in 2017. Our ability to rapidly build scaled positions in local communities has allowed us to grow to 28 anchor physician groups and 30 geographies as of December 31, 2025. As of December 31, 2025, the PCPs on our platform serve approximately 511,000 MA members and 114,000 Medicare fee-for-service (“FFS”) beneficiaries through nine Accountable Care Organizations (“ACOs”) through our participation in the Centers for Medicare & Medicaid Services’ (“CMS”) Accountable Care Organization Realizing Equity, Access, and Community Health (“ACO REACH”) Model and Medicare Shared Savings Program (“MSSP,” and together with ACO REACH, the “CMS ACO Models”) through its equity method investments.
Read full description ↓
On November 5, 2025, we received written notice (the “Notice”) from the NYSE informing us that we are no longer in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of our common stock was less than $1.00 per share over a consecutive 30 trading-day period ended November 4, 2025 (the “Price Criteria for Capital or Common Stock”).
We can regain compliance at any time within the six-month period following receipt of the Notice if, on the last trading day of any calendar month during the cure period (or the last trading day of the cure period), we have a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the prior 30 trading-day period ending on the last trading day of the applicable calendar month or the cure period. To regain compliance with the Price Criteria for Capital or Common Stock, we are pursuing a reverse stock split, subject to approval by our stockholders. We expect to seek stockholder approval at our special meeting to be held March 17, 2026. Under the NYSE Listed Company Manual, if we determine that we will cure the stock price deficiency by taking an action that will require stockholder approval, such as a reverse stock split, and we receive stockholder approval no later than our next general meeting of stockholders, the price condition will be deemed cured if, following stockholder approval and implementation of the approved action, the share price promptly exceeds $1.00 per share and the share price remains above that level for at least the following 30 trading days. See the risk entitled “The listing of shares of our common stock does not currently comply with the continued listing requirements of the NYSE, and if the NYSE delists our common stock, it could have an adverse impact on the trading, liquidity and market price of our common stock” under “